Ricciuti B - Search Results

1

Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy.

Scalera S, Ricciuti B, Marinelli D, Mazzotta M, Cipriani L, Bon G, Schiavoni G, Terrenato I, Di Federico A, Alessi JV, Fanciulli M, Ciuffreda L, De Nicola F, Goeman F, Caravagna G, Santini D, De Maria R, Cappuzzo F, Ciliberto G, Jamal-Hanjani M, Awad MM, McGranahan N, Maugeri-Saccà M. Scalera S, et al. Among authors: ricciuti b. Clin Cancer Res. 2024 Oct 1;30(19):4397-4411. doi: 10.1158/1078-0432.CCR-24-0626. Clin Cancer Res. 2024. PMID: 38980931

2

Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence.

Ricciuti B, Leonardi GC, Puccetti P, Fallarino F, Bianconi V, Sahebkar A, Baglivo S, Chiari R, Pirro M. Ricciuti B, et al. Pharmacol Ther. 2019 Apr;196:105-116. doi: 10.1016/j.pharmthera.2018.12.004. Epub 2018 Dec 4. Pharmacol Ther. 2019. PMID: 30521884 Review.

3

Targeting EGFR and ALK in NSCLC: current evidence and future perspective.

Bennati C, Paglialunga L, Ricciuti B, Metro G, Marcomigni L, Gili A, Crinò L. Bennati C, et al. Among authors: ricciuti b. Lung Cancer Manag. 2016 Jun;5(2):79-90. doi: 10.2217/lmt-2016-0005. Epub 2016 Jun 23. Lung Cancer Manag. 2016. PMID: 30643552 Free PMC article. Review.

4

Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient.

Ricciuti B, Metro G, Baglivo S, Colabrese D, Chiari R, Bennati C, Paglialunga L. Ricciuti B, et al. J Thorac Oncol. 2017 May;12(5):e51-e55. doi: 10.1016/j.jtho.2016.12.027. J Thorac Oncol. 2017. PMID: 28434516 Free article. No abstract available.

5

Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence.

Ricciuti B, Brambilla M, Metro G, Baglivo S, Matocci R, Pirro M, Chiari R. Ricciuti B, et al. Med Oncol. 2017 Jun;34(6):105. doi: 10.1007/s12032-017-0967-5. Epub 2017 Apr 25. Med Oncol. 2017. PMID: 28444624 Review.

6

First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC.

Ricciuti B, Chiari R. Ricciuti B, et al. Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S127-S130. doi: 10.21037/tlcr.2018.03.06. Transl Lung Cancer Res. 2018. PMID: 29782562 Free PMC article. No abstract available.

7

Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter?

De Giglio A, Porreca R, Brambilla M, Metro G, Prosperi E, Bellezza G, Pirro M, Chiari R, Ricciuti B. De Giglio A, et al. Among authors: ricciuti b. Thromb Res. 2018 Mar;163:51-53. doi: 10.1016/j.thromres.2017.12.004. Epub 2017 Dec 9. Thromb Res. 2018. PMID: 29353684 No abstract available.

8

Osimertinib.

Malapelle U, Ricciuti B, Baglivo S, Pepe F, Pisapia P, Anastasi P, Tazza M, Sidoni A, Liberati AM, Bellezza G, Chiari R, Metro G. Malapelle U, et al. Among authors: ricciuti b. Recent Results Cancer Res. 2018;211:257-276. doi: 10.1007/978-3-319-91442-8_18. Recent Results Cancer Res. 2018. PMID: 30069773 Review.

9

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence.

Ricciuti B, Genova C, Crinò L, Libra M, Leonardi GC. Ricciuti B, et al. Onco Targets Ther. 2019 Apr 30;12:3171-3179. doi: 10.2147/OTT.S177051. eCollection 2019. Onco Targets Ther. 2019. PMID: 31118670 Free PMC article.

10

Osimertinib for EGFR-mutant non-small cell lung cancer: place in therapy and future perspectives.

Ricciuti B. Ricciuti B. J Thorac Dis. 2019 Mar;11(Suppl 3):S249-S252. doi: 10.21037/jtd.2019.01.104. J Thorac Dis. 2019. PMID: 30997189 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

164 results

Search Page

Filters